AngioDynamics, a medical device company, has obtained CE Mark approval for its AngioVac venous drainage cannula and cardiopulmonary bypass circuit for use during extracorporeal bypass for around six hours.
The CE Mark also covers the approval of AngioVac cannula for removing fresh, soft thrombi or emboli.
AngioDynamics global peripheral vascular franchise senior vice president John Soto noted the AngioVac cannula and circuit have shown great promise in improving patient outcomes and reducing the cost of treatment when dealing with the removal of soft thrombus
"CE Mark approval makes this powerful tool available to physicians across the EU," Soto added.
The AngioVac Cannula incorporates a balloon-actuated, expandable, funnel-shaped distal tip for increasing flow, prevent clogging of the cannula and facilitate en bloc removal of undesirable intravascular material.
AngioDynamics’ international business senior vice president and general manager Stephen McGill noted the company recently exhibited the AngioVac cannula and circuit at the congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), and the reception was very encouraging.
"AngioDynamics has established itself as a leader and innovator in delivering minimally-invasive, image-guided solutions to interventional radiologists, vascular surgeons, cardiologists and surgical oncologists, and the AngioVac devices continue that tradition," McGill added.
The AngioVac venous drainage cannula and cardiopulmonary bypass circuit, when combined with other manufacturers’ filters, pumps and return cannula, comprise an extracorporeal bypass circuit that facilitates drainage, filtration and reinfusion of blood for around six hours.